Los buenos modales para la industria farmacéutica.

Improved Survival from Ovarian Cancer in Patients Treated in Phase III Trial Active Cancer Centres in the UK.

Clinical oncology (Royal College of Radiologists (Great Britain))·2016

Serial MRI scans help in assessing early response to neoadjuvant chemotherapy and tailoring breast cancer treatment.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2016

Targeted anti-vascular therapies for ovarian cancer: current evidence.

British journal of cancer·2013

A prospective randomised phase II trial of thalidomide with carboplatin compared with carboplatin alone as a first-line therapy in women with ovarian cancer, with evaluation of potential surrogate markers of angiogenesis.

European journal of gynaecological oncology·2011

A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2011

A randomised comparative trial of infusional ECisF versus conventional FEC as adjuvant chemotherapy in early breast cancer: the TRAFIC trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2010

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Lancet (London, England)·2026

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Lancet (London, England)·2026

Advancing the relevance of clinical trials for older patients.

Lancet (London, England)·2026

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Lancet (London, England)·2026

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Lancet (London, England)·2026

[THE PHARMACEUTICAL HUMANITIES IN RUSSIA AND FOR RUSSIA].

Problemy sotsial'noi gigieny, zdravookhraneniia i istorii meditsiny·2026

Research Needs in Philippine Pharmaceutical Sciences: A Qualitative Perspective from Regulatory and Clinical Research Sectors of the Pharmaceutical Industry.

Acta medica Philippina·2026

[The Role of Pharmaceutical Universities in Strengthening Japan's Drug Discovery Capabilities: A Pharmaceutical Industry Perspective].

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·2026

A randomized, open-label, three-period, cross-over, single intravenous or intramuscular dose, pharmacokinetics and bioequivalence study of vitamin K<sub>1</sub> in healthy adults.

Naunyn-Schmiedeberg's archives of pharmacology·2026

Academic Influence and Industry Funding in Platelet-Rich Plasma Injections: Coauthorship Network Analysis.

Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews·2026

Rupturing the Temporality of Pharmaceutical Patents: A Sketch for a New Temporal Economy of Pharmaceutical Markets.

The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics·2025

Videos de Experimentos Relacionados

Los buenos modales para la industria farmacéutica.

Videos de Conceptos Relacionados

Improved Survival from Ovarian Cancer in Patients Treated in Phase III Trial Active Cancer Centres in the UK.

Serial MRI scans help in assessing early response to neoadjuvant chemotherapy and tailoring breast cancer treatment.

Targeted anti-vascular therapies for ovarian cancer: current evidence.

A prospective randomised phase II trial of thalidomide with carboplatin compared with carboplatin alone as a first-line therapy in women with ovarian cancer, with evaluation of potential surrogate markers of angiogenesis.

A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer.

A randomised comparative trial of infusional ECisF versus conventional FEC as adjuvant chemotherapy in early breast cancer: the TRAFIC trial.

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Advancing the relevance of clinical trials for older patients.

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

[THE PHARMACEUTICAL HUMANITIES IN RUSSIA AND FOR RUSSIA].

Research Needs in Philippine Pharmaceutical Sciences: A Qualitative Perspective from Regulatory and Clinical Research Sectors of the Pharmaceutical Industry.

[The Role of Pharmaceutical Universities in Strengthening Japan's Drug Discovery Capabilities: A Pharmaceutical Industry Perspective].

A randomized, open-label, three-period, cross-over, single intravenous or intramuscular dose, pharmacokinetics and bioequivalence study of vitamin K<sub>1</sub> in healthy adults.

Academic Influence and Industry Funding in Platelet-Rich Plasma Injections: Coauthorship Network Analysis.

Rupturing the Temporality of Pharmaceutical Patents: A Sketch for a New Temporal Economy of Pharmaceutical Markets.

Videos de Experimentos Relacionados

Los buenos modales para la industria farmacéutica.

Videos de Conceptos Relacionados

Artículos Relacionados